Clinical Trial Update: The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a single intravenous dose of secukinumab or canakinumab in dry eye disease; the trial is completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• Canakinumab (canakinumab)
• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Dry Eye | Phase 2 | Status: COMPLETED | Results posted: 2013-01-07